Chroma Medicine Named to Endpoints 11 List of Most Promising Biotechs of 2023
Boston, MA., September 21, 2023 — Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced it was named to the Endpoints 11 2023 list of the most promising biotechs by Endpoints News. This annual award celebrates companies with leading-edge science that are pioneering the development of new medicines.
Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma is rapidly advancing a new class of therapeutics that harness epigenetics, nature’s innate mechanism for gene regulation, to achieve unparalleled control of gene expression without cutting, nicking, or altering the DNA sequence. After securing a $135 million Series B financing in early 2023, the company presented compelling in vivo data at the 2023 ASGCT Annual Meeting in Los Angeles showing 99% silencing of two distinct gene targets, demonstrating the promise of its epigenetic editing platform.
"We are honored to be acknowledged alongside our peer companies where together we are breaking new ground,” said Catherine Stehman-Breen, M.D., Chief Executive Officer of Chroma. "I am deeply grateful to our founders, investors, and partners for their ongoing support and to our Chroma team of dedicated and passionate individuals diligently working to progress our portfolio of highly differentiated epigenetic editing therapeutics to bring hope to patients living with serious diseases.”
Honorees were announced and recognized in an event held yesterday at the State Room in Boston. See the full list from Endpoints News.
About Chroma Medicine
Chroma Medicine is a biotechnology company pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company was founded by the world’s foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. For more information, please visit chromamedicine.com or follow us on LinkedIn and X (formerly known as Twitter).
Media Contact
Lia Dangelico
Verge Scientific Communications
540.303.0180